ACM
HRMY icon

Aisling Capital Management’s Harmony Biosciences HRMY Stock Holding History

Aisling Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-342,815
Closed -$16.7M – 20
2022
Q1 		$16.7M Sell
342,815
-12,600
-4% -$514K 9% 4
2021
Q4 		$15.2M Sell
355,415
-237,400
-40% -$9.46M 5.35% 6
2021
Q3 		$22.7M Sell
592,815
-250,000
-30% -$8.05M 4.53% 4
2021
Q2 		$23.8M Hold
842,815
– – 3.81% 4
2021
Q1 		$27.8M Hold
842,815
– – 5.01% 2
2020
Q4 		$30.5M Hold
842,815
– – 5.23% 3
2020
Q3 		$28.6M Buy
+842,815
New +$30.7M 9.13% 3

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aisling Capital Management's HRMY Position: Q2 2022 in Review

Aisling Capital Management sold out of Harmony Biosciences (HRMY) in Q2 2022, closing a stake of 342,815 shares — an estimated $16.7M sold.

Aisling Capital Management first reported a position in HRMY in Q3 2020 and held it in 7 quarters. The position peaked at $30.5M in Q4 2020. 183 funds tracked by Wall St. Rank hold HRMY as of Q2 2022.

  • Aisling Capital Management reported no remaining Harmony Biosciences position as of Q2 2022 after selling out during the quarter.
  • Aisling Capital Management sold 342,815 Harmony Biosciences shares in Q2 2022, an estimated $16.7M.
  • Aisling Capital Management first reported a position in Harmony Biosciences in Q3 2020 and held it in 7 quarters.
  • Aisling Capital Management's Harmony Biosciences position peaked at $30.5M in Q4 2020.
  • 183 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2022.

Based on Aisling Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.